Developer docs
API playgroundTry for free, no card

Search company profiles

Alcediag

Full company profile

uuid00064bq

Namestring
Alcediag
Legal namestring
ALCEDIAG
Company typeenum
Private
Founded yearint
2013
Descriptiontext

ALCEDIAG is a French precision diagnostics company headquartered in Montpellier and operating as a subsidiary of the diversified technology group ALCEN. Founded in 2013, the company develops blood-based molecular diagnostics for mental health, with its core focus on differentiating bipolar disorder from unipolar depression in adults presenting with moderate to severe depressive symptoms. Its lead product, EDIT-B, is a CE-marked in vitro diagnostic (IVDD 98/79/CE, Class 1) blood test that combines an 8-biomarker RNA editing panel with a machine learning algorithm incorporating patient clinical data (age, sex, treatments, addictions). Clinical validation across multiple European cohorts and 255+ patients has demonstrated sensitivity of 91%, specificity of 85%, and balanced accuracy of 0.901-0.904.

The company's technology backbone is the EDITECH platform, an integrated stack spanning DNA/RNA next-generation sequencing, epigenetic and RNA editing expertise, a bioinformatics pipeline, and AI/ML integration, with algorithms frozen during the operational phase to ensure safety, transparency, and reproducibility in a regulated medical context. ALCEDIAG's approach is protected by seven patent families and the company holds ISO 13485 certification. A second product, EDITOX, extends the platform into preclinical drug development via cell-based solutions that model drug impact on RNA editing.

Commercially, ALCEDIAG sells EDIT-B exclusively through medical biology laboratories on a per-test basis with results delivered to prescribing physicians within four weeks. The company launched in France in March 2024 via an exclusive partnership with Synlab (the test is branded myEDIT-B in Synlab markets), followed by Switzerland and Liechtenstein via Unilabs in late 2024/2025, and Italy in 2025 via Synlab. Reimbursement has not yet been secured; a 450-patient clinical utility study in France is underway to support payer decisions. The company's primary customer segments are psychiatrists and general practitioners prescribing the test, with clinical research partnerships (e.g., GHU Paris Psychiatrie & Neurosciences, Hospital Clinic Barcelona, Clariane) supporting evidence generation.

Short descriptiontext

Alcediag is a French precision diagnostics subsidiary of ALCEN that develops CE-marked blood tests combining RNA editing biomarkers with machine learning to differentiate bipolar disorder from unipolar depression, serving psychiatrists and patients through exclusive European laboratory partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMontpellier, France
HQ citystring
Montpellier
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision diagnostics, RNA editing biomarkers, molecular blood testing, psychiatric differential diagnosis, in vitro diagnostics
Industry2 codes
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1EDIT-B Diagnostic Test
TypeOne Time License
Description

Blood test for differentiating unipolar depression from bipolar disorder, prescribed by psychiatrists and general practitioners. Test performed exclusively in medical biology laboratories with results delivered within 4 weeks. Revenue generated per test performed.

alcediag-alcen.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Prescription-based diagnostic test
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Available by prescription only in participating European countries through Synlab and Unilabs laboratory partners.

alcediag-alcen.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Alcediag develops and commercializes RNA editing-based in vitro diagnostic blood tests, primarily EDIT-B®, which combines an 8-biomarker RNA editing panel with a machine-learning algorithm to differentiate bipolar disorder from unipolar depression in adult patients with moderate-to-severe depression. The company also offers EDITOX®, a cell-based preclinical tool for pharmaceutical drug development, all built on its integrated EDITECH® sequencing, bioinformatics, and AI platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Sensitivity and specificity superior to 80% demonstrated in clinical trials
+3 more records
Product overview1 text field

ALCEDIAG is an innovative diagnostic company specializing in precision psychiatry, offering a portfolio of blood tests, monitoring solutions, and companion diagnostics for mental health. The core product is EDIT-B®, a CE-marked blood test that differentiates unipolar depression from bipolar disorder using RNA editing-based biomarkers and AI. EDITOX® provides cell-based preclinical solutions for drug development applications. EDITECH® serves as the integrated technology platform, combining DNA/RNA sequencing, bioinformatics, and AI capabilities that underpin the diagnostic products. The company develops all solutions in-house, with seven patent families protecting its unique approach.

Product and service2 records
1EDIT-B®
CategoryIn Vitro Diagnostic Test
Description

CE-marked in vitro diagnostic blood test that uses an 8-biomarker RNA editing panel combined with machine-learning algorithms to differentiate bipolar disorder from unipolar depression in adults presenting with moderate to severe depression. Prescribed by psychiatrists and general practitioners and performed in medical biology laboratories with results delivered within four weeks; demonstrated sensitivity above 80% and specificity of 85% in clinical validation cohorts.

2EDITOX®
CategoryPreclinical Research Tool
Description

Cell-based solution designed to mimic the impact of drugs on RNA editing, used as a preclinical tool by pharmaceutical companies to advance new drug development and assess RNA editing responses to compounds.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-10-15
Description

Real-world clinical study collaboration presenting data on high acceptability of myEDIT-B test in routine care. Study involved 63 adult patients in France and Spain presented at ECNP congress.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive European partnership with Synlab group, Europe's market leader in medical laboratories, which has become myEDIT-B test's distributor. Test available in France and Italy under the myEDIT-B brand.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

EDIT-B Consortium co-funded by EIT Health and European Commission. Project aims to validate and commercialize a high-performance blood test to diagnose bipolar disorder using RNA editing biomarkers and AI.

4NeuroDeRisk
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Innovative Medicines Initiative (IMI2) project providing tools for preclinical prediction of adverse effects of pharmaceuticals on the nervous system to de-risk drug candidates in R&D phases.

alcediag-alcen.com
Strategic tierCoreTypeTechnology or Integration
Description

Recurring partnership with Sys2Diag, a laboratory from CNRS (French National Center for Scientific Research), running cutting-edge research for innovation in medical diagnosis and next-generation medical interactives devices engineering.

6GHU Paris Psychiatrie & Neurosciences
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Recurring partnership with leading hospital player in mental illnesses and nervous system in France. GHU is a clinical trial site for EDIT-B studies.

alcediag-alcen.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Recurring partnership with leading healthcare, research and teaching center in Barcelona. Dr. Eduard Vieta serves as principal investigator and leads the bipolar disorder department.

Strategic tierMinorTypeGTM or Marketing Partner
Description

M accreditation from MIMS (House of Innovation in Personalized Medicine) for EDIT-B test. Recognition of innovation and trust granted by MIMS Scientific and Strategic Committee.

9Villa M / Groupe Pasteur Mutualité
Strategic tierMinorTypeGTM or Marketing Partner
Description

iMpulsion-Villa M acceleration programme, an 8-month program bringing together innovative health and e-health startups to support deployment of innovative healthcare products.

alcediag-alcen.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Collaboration with combined company and association dedicated to supporting people with bipolar disorder. Founder Clément Baissat developed 4-step approach: AWARE – ACCEPT – GUIDE – SUPPORT. Mission to reduce stigma and help patients from first symptoms.

Strategic tierMinorTypeOthers
Description

Member of France Biotech, the French trade association of biotechnology companies.

Strategic tierMinorTypeOthers
Description

Member of Medicen, the Île-de-France/Paris competitiveness cluster focusing on health, gathering more than 510 health innovators.

Strategic tierMinorTypeOthers
Description

Member of Eurobiomed, the South of France competitiveness cluster dedicated to Healthtech, bringing together more than 400 industrial players, research laboratories, and universities.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage precision psychiatry company using biomarkers, EEG, and AI/ML to stratify patients with depression and other psychiatric conditions. Directly comparable to Alcediag in combining objective biological signals with machine learning to enable differential diagnosis and treatment selection in mental health.

TypeDirect peer
Description

Commercial molecular diagnostics company that develops RNA-expression and genomic tests to resolve diagnostic ambiguity (e.g., in oncology). Highly comparable business model to Alcediag: laboratory-developed or IVD tests using RNA/genomic biomarkers, distributed via central labs, protected by IP and clinical validation.

TypeBroad incumbent
Description

Established molecular diagnostics company with a portfolio of germline and tumour genomic tests commercialised through specialty labs. Comparable to Alcediag in business model (proprietary biomarker tests, lab-based delivery, IP-protected menu) but operates at much greater scale and across oncology/women's health rather than psychiatry.

TypeBroad incumbent
Description

Roche-owned molecular diagnostics leader offering NGS-based profiling tests. Comparable to Alcediag in using NGS + AI/bioinformatics to convert complex molecular data into clinically actionable reports, but operating at vastly larger scale and focused on oncology rather than mental health.

TypeBroad incumbent
Description

Diversified molecular diagnostics company (Cologuard, Oncotype DX, etc.) commercialising biomarker-based tests through clinical-lab channels. Similar diagnostic-platform commercial model to Alcediag, though at a much larger scale and across multiple non-psychiatric indications.

TypeBroad incumbent
Description

Global provider of molecular diagnostics assays, sample-prep technologies, and bioinformatics. Comparable to Alcediag in supplying RNA/DNA-based diagnostic workflows and bioinformatics pipelines to clinical labs, but as a tools-and-consumables provider rather than a test developer.

TypeEmerging player
Description

Neuroscience company developing therapeutics for depression and other CNS indications with biomarker-driven patient selection. Adjacent to Alcediag's mental-health focus and shares the precision-psychiatry thesis, but operates on the therapeutic rather than diagnostic side.

TypeEmerging player
Description

Mental-health company developing psilocybin therapy for treatment-resistant depression with biomarker-driven patient stratification. Comparable to Alcediag in targeting the depression-treatment paradigm with precision approaches, though focused on therapy delivery rather than diagnostic testing.

TypeEmerging player
Description

UK-based CNS research organisation developing experimental medicine tools and biomarkers for depression and other psychiatric conditions. Directly comparable to Alcediag in its focus on objective CNS biomarkers to support psychiatric drug development and differential diagnosis.

10Genomics England
TypeOthers
Description

UK government-owned organisation sequencing patient genomes at population scale to enable rare-disease and cancer diagnostics. Comparable to Alcediag as an ecosystem enabler in genomic/RNA-based diagnostics, though operating as a public-sector platform rather than a commercial test developer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alcediag

Molecular Diagnosticsalcediag-alcen.com

Alcediag is a French precision diagnostics subsidiary of ALCEN that develops CE-marked blood tests combining RNA editing biomarkers with machine learning to differentiate bipolar disorder from unipolar depression, serving psychiatrists and patients through exclusive European laboratory partners.

What Alcediag does

ALCEDIAG is a French precision diagnostics company headquartered in Montpellier and operating as a subsidiary of the diversified technology group ALCEN. Founded in 2013, the company develops blood-based molecular diagnostics for mental health, with its core focus on differentiating bipolar disorder from unipolar depression in adults presenting with moderate to severe depressive symptoms. Its lead product, EDIT-B, is a CE-marked in vitro diagnostic (IVDD 98/79/CE, Class 1) blood test that combines an 8-biomarker RNA editing panel with a machine learning algorithm incorporating patient clinical data (age, sex, treatments, addictions). Clinical validation across multiple European cohorts and 255+ patients has demonstrated sensitivity of 91%, specificity of 85%, and balanced accuracy of 0.901-0.904.

The company's technology backbone is the EDITECH platform, an integrated stack spanning DNA/RNA next-generation sequencing, epigenetic and RNA editing expertise, a bioinformatics pipeline, and AI/ML integration, with algorithms frozen during the operational phase to ensure safety, transparency, and reproducibility in a regulated medical context. ALCEDIAG's approach is protected by seven patent families and the company holds ISO 13485 certification. A second product, EDITOX, extends the platform into preclinical drug development via cell-based solutions that model drug impact on RNA editing.

Commercially, ALCEDIAG sells EDIT-B exclusively through medical biology laboratories on a per-test basis with results delivered to prescribing physicians within four weeks. The company launched in France in March 2024 via an exclusive partnership with Synlab (the test is branded myEDIT-B in Synlab markets), followed by Switzerland and Liechtenstein via Unilabs in late 2024/2025, and Italy in 2025 via Synlab. Reimbursement has not yet been secured; a 450-patient clinical utility study in France is underway to support payer decisions. The company's primary customer segments are psychiatrists and general practitioners prescribing the test, with clinical research partnerships (e.g., GHU Paris Psychiatrie & Neurosciences, Hospital Clinic Barcelona, Clariane) supporting evidence generation.

Alcediag firmographics

Firmographics
Name
Alcediag
Legal name
ALCEDIAG
Website
https://alcediag-alcen.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Alcediag is a French precision diagnostics subsidiary of ALCEN that develops CE-marked blood tests combining RNA editing biomarkers with machine learning to differentiate bipolar disorder from unipolar depression, serving psychiatrists and patients through exclusive European laboratory partners.
Ownership category
akta.pro rank

Alcediag industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Precision diagnostics
  • RNA editing biomarkers
  • Molecular blood testing
  • Psychiatric differential diagnosis
  • In vitro diagnostics

Where Alcediag is headquartered

Location

Headquarters

HQ city
Montpellier
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Alcediag business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. EDIT-B Diagnostic Test: Blood test for differentiating unipolar depression from bipolar disorder, prescribed by psychiatrists and general practitioners. Test performed exclusively in medical biology laboratories with results delivered within 4 weeks. Revenue generated per test performed.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goPrescription-based diagnostic test

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Alcediag product offering

Product offering

Core offering

Alcediag develops and commercializes RNA editing-based in vitro diagnostic blood tests, primarily EDIT-B®, which combines an 8-biomarker RNA editing panel with a machine-learning algorithm to differentiate bipolar disorder from unipolar depression in adult patients with moderate-to-severe depression. The company also offers EDITOX®, a cell-based preclinical tool for pharmaceutical drug development, all built on its integrated EDITECH® sequencing, bioinformatics, and AI platform.

Product overview

ALCEDIAG is an innovative diagnostic company specializing in precision psychiatry, offering a portfolio of blood tests, monitoring solutions, and companion diagnostics for mental health. The core product is EDIT-B®, a CE-marked blood test that differentiates unipolar depression from bipolar disorder using RNA editing-based biomarkers and AI. EDITOX® provides cell-based preclinical solutions for drug development applications. EDITECH® serves as the integrated technology platform, combining DNA/RNA sequencing, bioinformatics, and AI capabilities that underpin the diagnostic products. The company develops all solutions in-house, with seven patent families protecting its unique approach.

Differentiator

Problem solved

Functional benefit

Products and services

  • EDIT-B® CE-marked in vitro diagnostic blood test that uses an 8-biomarker RNA editing panel combined with machine-learning algorithms to differentiate bipolar disorder from unipolar depression in adults presenting with moderate to severe depression. Prescribed by psychiatrists and general practitioners and performed in medical biology laboratories with results delivered within four weeks; demonstrated sensitivity above 80% and specificity of 85% in clinical validation cohorts.
  • EDITOX® Cell-based solution designed to mimic the impact of drugs on RNA editing, used as a preclinical tool by pharmaceutical companies to advance new drug development and assess RNA editing responses to compounds.

Quantifiable outcome

  • Sensitivity and specificity superior to 80% demonstrated in clinical trials
  • +3 more outcomes

Companies that use Alcediag

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Alcediag technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Alcediag partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered minor and core.

  • ClarianeminorStrategic or Co-development Partner · 15 October 2025Real-world clinical study collaboration presenting data on high acceptability of myEDIT-B test in routine care. Study involved 63 adult patients in France and Spain presented at ECNP congress.
  • Synlab GroupcoreChannel Partner/ Reseller/ DistributorExclusive European partnership with Synlab group, Europe's market leader in medical laboratories, which has become myEDIT-B test's distributor. Test available in France and Italy under the myEDIT-B brand.
  • EIT HealthcoreStrategic or Co-development PartnerEDIT-B Consortium co-funded by EIT Health and European Commission. Project aims to validate and commercialize a high-performance blood test to diagnose bipolar disorder using RNA editing biomarkers and AI.
  • NeuroDeRiskminorStrategic or Co-development PartnerInnovative Medicines Initiative (IMI2) project providing tools for preclinical prediction of adverse effects of pharmaceuticals on the nervous system to de-risk drug candidates in R&D phases.
  • Sys2Diag / CNRScoreTechnology or IntegrationRecurring partnership with Sys2Diag, a laboratory from CNRS (French National Center for Scientific Research), running cutting-edge research for innovation in medical diagnosis and next-generation medical interactives devices engineering.
  • GHU Paris Psychiatrie & NeurosciencescoreStrategic or Co-development PartnerRecurring partnership with leading hospital player in mental illnesses and nervous system in France. GHU is a clinical trial site for EDIT-B studies.
  • Hospital Clinic BarcelonacoreStrategic or Co-development PartnerRecurring partnership with leading healthcare, research and teaching center in Barcelona. Dr. Eduard Vieta serves as principal investigator and leads the bipolar disorder department.
  • MIMSminorGTM or Marketing PartnerM accreditation from MIMS (House of Innovation in Personalized Medicine) for EDIT-B test. Recognition of innovation and trust granted by MIMS Scientific and Strategic Committee.
  • Villa M / Groupe Pasteur MutualitéminorGTM or Marketing PartneriMpulsion-Villa M acceleration programme, an 8-month program bringing together innovative health and e-health startups to support deployment of innovative healthcare products.
  • HopeStageminorGTM or Marketing PartnerCollaboration with combined company and association dedicated to supporting people with bipolar disorder. Founder Clément Baissat developed 4-step approach: AWARE – ACCEPT – GUIDE – SUPPORT. Mission to reduce stigma and help patients from first symptoms.
  • France BiotechminorOthersMember of France Biotech, the French trade association of biotechnology companies.
  • MedicenminorOthersMember of Medicen, the Île-de-France/Paris competitiveness cluster focusing on health, gathering more than 510 health innovators.
  • EurobiomedminorOthersMember of Eurobiomed, the South of France competitiveness cluster dedicated to Healthtech, bringing together more than 400 industrial players, research laboratories, and universities.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Alcediag competitors and assessment

Company assessment

Direct peers

  • Alto Neuroscience: Clinical-stage precision psychiatry company using biomarkers, EEG, and AI/ML to stratify patients with depression and other psychiatric conditions. Directly comparable to Alcediag in combining objective biological signals with machine learning to enable differential diagnosis and treatment selection in mental health.
  • Veracyte: Commercial molecular diagnostics company that develops RNA-expression and genomic tests to resolve diagnostic ambiguity (e.g., in oncology). Highly comparable business model to Alcediag: laboratory-developed or IVD tests using RNA/genomic biomarkers, distributed via central labs, protected by IP and clinical validation.

Broad incumbents

  • Myriad Genetics: Established molecular diagnostics company with a portfolio of germline and tumour genomic tests commercialised through specialty labs. Comparable to Alcediag in business model (proprietary biomarker tests, lab-based delivery, IP-protected menu) but operates at much greater scale and across oncology/women's health rather than psychiatry.
  • Foundation Medicine (Roche): Roche-owned molecular diagnostics leader offering NGS-based profiling tests. Comparable to Alcediag in using NGS + AI/bioinformatics to convert complex molecular data into clinically actionable reports, but operating at vastly larger scale and focused on oncology rather than mental health.
  • Exact Sciences: Diversified molecular diagnostics company (Cologuard, Oncotype DX, etc.) commercialising biomarker-based tests through clinical-lab channels. Similar diagnostic-platform commercial model to Alcediag, though at a much larger scale and across multiple non-psychiatric indications.
  • QIAGEN: Global provider of molecular diagnostics assays, sample-prep technologies, and bioinformatics. Comparable to Alcediag in supplying RNA/DNA-based diagnostic workflows and bioinformatics pipelines to clinical labs, but as a tools-and-consumables provider rather than a test developer.

Emerging players

  • Sage Therapeutics: Neuroscience company developing therapeutics for depression and other CNS indications with biomarker-driven patient selection. Adjacent to Alcediag's mental-health focus and shares the precision-psychiatry thesis, but operates on the therapeutic rather than diagnostic side.
  • COMPASS Pathways: Mental-health company developing psilocybin therapy for treatment-resistant depression with biomarker-driven patient stratification. Comparable to Alcediag in targeting the depression-treatment paradigm with precision approaches, though focused on therapy delivery rather than diagnostic testing.
  • P1vital: UK-based CNS research organisation developing experimental medicine tools and biomarkers for depression and other psychiatric conditions. Directly comparable to Alcediag in its focus on objective CNS biomarkers to support psychiatric drug development and differential diagnosis.

Others

  • Genomics England: UK government-owned organisation sequencing patient genomes at population scale to enable rare-disease and cancer diagnostics. Comparable to Alcediag as an ecosystem enabler in genomic/RNA-based diagnostics, though operating as a public-sector platform rather than a commercial test developer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Alcediag social profiles

Digital presence

Alcediag compliance and trust

Trust signal

Compliance2 records

Alcediag financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alcediag leadership team

Management profile

Number of profiles

Profiles3 records

Alcediag funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alcediag M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alcediag

What does Alcediag do?

Alcediag develops and commercializes RNA editing-based in vitro diagnostic blood tests, primarily EDIT-B®, which combines an 8-biomarker RNA editing panel with a machine-learning algorithm to differentiate bipolar disorder from unipolar depression in adult patients with moderate-to-severe depression. The company also offers EDITOX®, a cell-based preclinical tool for pharmaceutical drug development, all built on its integrated EDITECH® sequencing, bioinformatics, and AI platform.

Is Alcediag a public or private company?

Alcediag is a private company. It is classified as corporate owned and is currently operating.

When was Alcediag founded?

Alcediag was founded in 2013. It employs 11 to 50 people.

Where is Alcediag based?

Alcediag is headquartered in Montpellier, France, in the Europe region.

How does Alcediag make money?

One revenue line is on record: EDIT-B Diagnostic Test.

Who are Alcediag's main competitors?

Direct peers on record are Alto Neuroscience and Veracyte. Broad incumbents are Myriad Genetics, Foundation Medicine (Roche), Exact Sciences and QIAGEN. Emerging players are Sage Therapeutics, COMPASS Pathways and P1vital. Genomics England is listed as an others.

Does Alcediag have an API?

No public API is recorded for Alcediag.

What industry is Alcediag in?

Alcediag's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenomeWebFrench Dx Firm Alcediag Aims to Expand Reach of Test for Depression, Bipolar DisorderFrench precision psychiatry firm Alcediag announced plans to expand its blood test, MyEDIT-B, for differentiating depression and bipolar disorder across Europe after launching in France, Switzerland, and Italy. The test relies on RNA-editing biomarkers, and recent clinical trials showed it has approximately 83% accuracy, with the company aiming for broader regulatory approval and geographic expansion.PR NewswireClariane & ALCEDIAG present real-world data confirming the high acceptability of the myEDIT-B test in routine care at the European Congress of Neuropsychopharmacology (ECNP)A real-world acceptability study of the myEDIT-B blood test, developed by ALCEDIAG to distinguish unipolar from bipolar depression, was presented at the ECNP 2025 congress in Amsterdam. The study, conducted across Clariane's mental health clinic networks in France and Spain with 63 patients, showed strong clinical utility with 83% of psychiatrists reporting the test helped guide treatment and 100% saying it strengthened the therapeutic alliance. The findings support integrating precision diagnostic tools into psychiatric care pathways to address the average eight-year delay in bipolar disorder diagnosis.PR NewswireALCEDIAG y SYNLAB aúnan fuerzas en EuropaALCEDIAG and SYNLAB have announced a partnership to make EDIT-B™, a CE-marked in vitro blood test, available across Europe to differentiate bipolar disorder from depression. The test, which measures RNA editing for specific biomarkers, was clinically validated in two independent cohort studies showing sensitivity and specificity above 80%. EDIT-B™ is currently available in Italy, with expansion to France and Switzerland planned for 2023, gradually rolling out across SYNLAB’s 26 European countries.PR NewswireALCEDIAG et SYNLAB s'associent en Europe pour lutter contre le retard de diagnostic du trouble bipolaire à l'aide du test EDIT-B™ALCEDIAG and SYNLAB announced a partnership to make EDIT-B™, a CE-marked in-vitro blood test that differentiates bipolar disorder from depression, available across Europe. The test addresses a significant diagnostic gap, as bipolar disorder affects an estimated 2.3% of the European population with an average 8-to-10-year delay between symptom onset and diagnosis. EDIT-B™ uses RNA editing and AI technology with sensitivity and specificity above 80%, validated through two clinical studies, and is now available in Italy before planned expansion to France and Switzerland in 2023.PR NewswireALCEDIAG and SYNLAB join forces in Europe to fight diagnostic delay of bipolar disorder with the EDIT-B™ testALCEDIAG and SYNLAB have partnered to launch EDIT-B™, the world's first CE-marked in-vitro blood test designed to differentiate bipolar disorder from depression, announced at the 31st EPA congress. The test, based on RNA editing and AI technology, addresses a diagnostic delay of 8-10 years that affects approximately 2.3% of the European population, offering sensitivity and specificity above 80%. EDIT-B™ is now available in Italy and will expand to France and Switzerland during 2023, with SYNLAB operating in 26 European countries.PR NewswireFirst Blood Test to Diagnose Bipolar DisorderAlcediag, in collaboration with academic and clinical partners, has developed the first diagnostic blood test for bipolar disorder based on a panel of six specific RNA biomarkers. The study, published in Nature: Translational Psychiatry, demonstrates high sensitivity and specificity in differentiating bipolar depression from unipolar depression. This development initiates the EDIT-B project, a European initiative aimed at achieving regulatory validation under IVDR standards.PR NewswireOn World Bipolar Day ALCEDIAG Announces EIT Health Supported EDIT-B Consortium Validating Innovative Blood Diagnostic Test for Bipolar DisorderALCEDIAG announced the launch of the EDIT-B Consortium, a European public-private partnership supported by EIT Health aimed at validating a blood diagnostic test for bipolar disorder. The consortium, with a budget of €5.2 million, will operate for three years to utilize RNA editing biomarkers and AI to improve diagnostic accuracy and reduce delays.EuropaWireOn World Bipolar Day ALCEDIAG announces EIT Health supported EDIT-B Consortium validating innovative blood diagnostic test for bipolar disorderAlcediag launched the EDIT-B Consortium, an EIT Health-supported public-private partnership, to validate a blood test for bipolar disorder. The €5.2M project, co-funded by EIT Health and partners, aims to use RNA editing biomarkers and AI to improve diagnosis, which is often delayed by 7.5 years.